CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation The mSToPS Randomized Clinical Trial Select Drug-Drug Interactions With Direct Oral Anticoagulants Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study Mode of Death in Heart Failure With Preserved Ejection Fraction

Original Research

JOURNAL:CBSMD Article Link

无复流现象

CBSMD

Pre-reading

2001年,Eeckhout和Kern将无复流现象(No-Flow Phenomenon)定义为冠状动脉循环中某一特定血管节段虽心肌灌注不足,但无机械性血管阻塞(mechanical vessel obstruction)冠状动脉造影证据。经皮冠状动脉介入治疗支架置入后在明确没有可见残余狭窄后,术者将首要关注冠状动脉血流,若发生无复流现象,或将进一步影响预后及左心室重构,增加不良心脏事件的风险。因此熟知可预防无复流现象的策略、药物(冠状动脉内注射腺苷intracoronary adenosine, 硝普钠nitropusside)和非药物(低体温法induced hypothermia)等干预法对提高介入质量、改善患者预后的重要性不言而喻。